Nucleai, Propath partner on immuno-oncology panel

LabPulse.com staff writers
Sep 20, 2022
2020 03 25 23 27 0591 Hands Shaking Deal 400

Nucleai on Wednesday announced a collaboration with Propath UK to develop and validate a 30-plex immunofluorescence panel focused on protein targets relevant to immuno-oncology.

Propath will develop a novel protocol using the Lunaphore Comet platform for analysis of 30 high-value protein targets from a single tissue section. The platform enables rapid development of highly multiplexed panels, with robust and reproducible staining, Nucleai said.

In conjunction with Nucleai's validated artificial intelligence (AI) assay, the panel can be used to unlock insights from immunotherapy trials and inform the development of novel biomarkers and companion diagnostics (CDx), Nuclei added.

Latest in Gene silencing and gene editing
Researcher
Engineered Cas clears barrier to antiviral CRISPR therapies
April 19, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Licensed under Creative Commons
Reversible, multiplex CRISPR system enhances efficacy of CAR-T cell therapy
February 28, 2024
Science Genome Sequence Dna Map Social
Intellia Therapeutics, ReCode Therapeutics to collaborate on genomic medicines for CF
February 16, 2024
Related Stories
Pathology Digital Workstation Microscope Social
Pathology and AI
Nucleai, Mayo Clinic partner on digital pathology
Scientists Collaborate Team Social
Collaboration
Nucleai, Adlai Nortye collaborate on biomarkers for clinical trials
Colorectal Cancer Social
RUO
Nucleai to present data on multiplex immunofluorescence analysis for colorectal cancer research
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Gene silencing and gene editing
Engineered Cas clears barrier to antiviral CRISPR therapies
By Nick Paul Taylor
Researchers have engineered a Cas enzyme to enhance activity against RNA viruses, resulting in a system that completely blocked the replication of various SARS-CoV-2 strains.
April 19, 2024
Researcher
Gene-based technique shows potential for rapid diagnostics
By LabPulse.com staff writers
Biomedical engineers have developed a new gene-based approach which can be used on test strips for rapid, on-the-spot disease detection with accuracy comparable to that of lab-based polymerase chain reaction (PCR) tests.
March 7, 2024
Sequencing Virus Social
Reversible, multiplex CRISPR system enhances efficacy of CAR-T cell therapy
By Nick Paul Taylor
A CRISPR system that uses Cas13d to make reversible changes to the expression of multiple genes could overcome limitations that are holding back CAR-T cell therapies, a paper published in Cell suggests.
February 28, 2024
Licensed under Creative Commons
Intellia Therapeutics, ReCode Therapeutics to collaborate on genomic medicines for CF
By LabPulse.com staff writers
Gene-editing firm Intellia Therapeutics and biotech company ReCode Therapeutics have entered into a strategic collaboration aimed at developing genomic medicines for the treatment of cystic fibrosis (CF).
February 16, 2024
Science Genome Sequence Dna Map Social
CRISPR and nanopore technology enable sensitive and specific mpox detection
By Nick Paul Taylor
A test that combines CRISPR gene editing and nanopore sensing technology could accelerate the detection of mpox and other pathogens, according to a paper published in Biosensors and Bioelectronics.
February 16, 2024
3 D Monkeypox Infecting Cell Social
Sensorion receives clinical trial approval for congenital deafness gene therapy
By LabPulse.com staff writers
French biotech firm Sensorion has received approval to initiate a phase I and II clinical trial in France of SENS-501 (the OTOF-GT program), its gene therapy for gene-mediated hearing impairment.
January 22, 2024
Clinical Trial Data Network Social
First FDA-approved CRISPR-based gene therapy cleared for 2nd indication
By LabPulse.com staff writers
A month after the U.S. Food and Drug Administration (FDA) approved Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, the agency has given it a second U.S. regulatory approval ahead of schedule.
January 17, 2024
Cell Gene Therapy Dna Social
Genevant Sciences forges $114M deal with Tome Biosciences on liver disease gene therapy
By LabPulse.com staff writers
Biotech firm Genevant Sciences will collaborate with biotech startup Tome Biosciences on an in vivo gene editing treatment for a rare liver disorder.
January 16, 2024
Dna Genetic Engineering Single Nucleotide Social
IGI, Danaher launch CRISPR gene therapy research center
By LabPulse.com staff writers
Danaher and the Innovative Genomics Institute (IGI) have launched a collaborative research center aimed at developing CRISPR-based gene therapies for a wide array of diseases.
January 12, 2024
Crispr Cas9 Gene Editing Social
Gene therapy, companion diagnostic hit milestones for hemophilia A
By Liz Carey
Six months after the FDA approved a one-time gene therapy for severe hemophilia A reportedly priced around $2.5 million per patient, the Center for Inherited Blood Disorders, a 340B treatment center in California, has announced the drug's first infusion.
January 11, 2024
Blood Cells Vessel Social
Tome Biosciences acquires Replace Therapeutics in $65M deal
By LabPulse.com staff writers
Less than a month after Tome Biosciences emerged with $213 million in funding, the gene editing company will acquire Replace Therapeutics for $65 million in upfront and near-term milestones, with a total deal value of up to $185 million.
January 5, 2024
Dna Sequence Social
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
By LabPulse.com staff writers
Biotech firm KSQ Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I and II trial of KSQ-001EX, KSQ’s CRISPR-Cas9 engineered tumor-infiltrating lymphocyte program.
November 29, 2023
Crispr Cas9 Gene Editing Social
Page 1 of 7
Next Page